 | Up a level |
Ben Khaled, Najib, Seidensticker, Max, Ricke, Jens, Mayerle, Julia, Oehrle, Bettina, Roessler, Daniel, Teupser, Daniel, Ehmer, Ursula, Bitzer, Michael 
ORCID: 0000-0002-4463-8263, Waldschmidt, Dirk, Fuchs, Martin, Reuken, Philipp A., Lange, Christian M., Wege, Henning, Kandulski, Arne, Dechene, Alexander, Venerito, Marino, Berres, Marie-Luise, Luedde, Tom ORCID: 0000-0002-6288-8821, Kubisch, Ilja, Reiter, Florian P. and De Toni, Enrico N.
(2022).
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Future Oncol., 18 (12).
S. 1423 - 1436.
LONDON:
FUTURE MEDICINE LTD.
ISSN 1744-8301
De Toni, Enrico N., Kubisch, Ilja, Ben Khaled, Najib, Ricke, Jens, Mayerle, Julia, Ehmer, Ursula, Waldschmidt, Dirk, Roessler, Daniel Christoph, Oehrle, Bettina, Bitzer, Michael, Kandulski, Arne, Reuken, Philipp A., Wege, Henning and Seidensticker, Max (2022). Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial. J. Clin. Oncol., 40 (4). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755